<DOC>
	<DOCNO>NCT02520934</DOCNO>
	<brief_summary>evaluate combination therapy Miglustat enzyme replacement therapy ( ERT ) Gaucher disease</brief_summary>
	<brief_title>Miglustat Gaucher Disease Type IIIB</brief_title>
	<detailed_description>understand Miglustat ( glucosylceramide synthase inhibitor ) could improve neuropathy patient Gaucher disease</detailed_description>
	<mesh_term>Gaucher Disease</mesh_term>
	<mesh_term>Miglustat</mesh_term>
	<mesh_term>1-Deoxynojirimycin</mesh_term>
	<criteria>Case_Miglustat 1 . Confirmed diagnosis Gaucher Disease : blood test show lack beta glucocerebrosidase , find L444P homozygous GBA gene . 2 . Aged 6 year old . 3 . Already regular ERT ( 30120 IU/kg/ every 2 week ) least year ; dosage frequency ERT change recent 3 month . 1 . History tremor abnormal extremity perception ( pain , numbness , tingle etc . ) 2 . Abnormal kidney function . 3 . Pregnant plan baby ( potentially pregnant patient need transfer gynecologist test promise proper contraception measure ) . 4 . Allergic Miglustat . Control_normal Inclusion Criteria 1 . Age 618 year 2 . No significant physical , mental , psychiatric problem Exclusion criteria 1 . Children eye disease ( include myopia , hyperopia , Astigmatism )</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Enzyme Replacement Therapy</keyword>
	<keyword>Miglustat</keyword>
	<keyword>Gaucher Disease</keyword>
</DOC>